Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations

Brian E. Davies*

Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA

Tel: +1-973-235-2053; Fax: +1-973-235-5635; E-mail: brian.davies@roche.com

Influenza is a transmissible viral pathogen that continues to cause considerable morbidity and mortality. Oseltamivir (Tamiflu®; F. Hoffmann-La Roche Ltd) is an orally administered antiviral for the treatment and prevention of its debilitating symptoms. Oseltamivir (Tamiflu®; F. Hoffmann-La Roche Ltd) is an orally administered antiviral for the management of influenza A and B infections in children ≥1 year and adults of all ages. It is a widely used medication, with global experience now exceeding 65 million treatment courses. For therapeutic use, oseltamivir is taken as a twice-daily regimen for 5 consecutive days, while for prophylaxis it is taken once-daily for up to 42 days. Adults take oseltamivir at a standard dose of 75 mg, while children receive unit doses that are selected on the basis of body weight. Oral capsule (35, 40 and 75 mg) and suspension formulations are now readily available. Oseltamivir is ingested in the form of an oral prodrug (oseltamivir phosphate) that is rapidly converted by hepatic esterases into the active metabolite, oseltamivir carboxylate. Oseltamivir carboxylate has high bioavailability and penetrates sites of infection at concentrations that are sufficient to inhibit viral replication. The pharmacokinetics of oseltamivir and oseltamivir carboxylate are dose proportional after repeated doses of up to 500 mg twice daily. This predictable profile means that oseltamivir is suitable for use in diverse patient populations, which may include young children and elderly patients, various ethnic groups and those with renal or hepatic impairment. As the potential for drug interactions is low, oseltamivir is also suitable for use in patients with co-morbid conditions who are likely to be receiving concomitant medications.

Keywords: mechanism of action, dosing, drug interactions

Introduction

Influenza is an infectious viral agent that continues to cause considerable morbidity and mortality. The pathogenicity of the influenza virus is now well understood, and this has led to the development of a range of antiviral agents for the treatment and prevention of its debilitating symptoms. Oseltamivir (Tamiflu®; F. Hoffmann-La Roche Ltd) is an orally administered antiviral for the management of influenza A and B infections in children ≥1 year and adults of all ages. It is a widely used medication, with global experience now exceeding 65 million treatment courses. For therapeutic use, oseltamivir is taken as a twice-daily regimen for 5 consecutive days, while for prophylaxis it is taken once-daily for up to 42 days. Adults take oseltamivir at a standard dose of 75 mg, while children receive unit doses that are selected on the basis of body weight. Oral capsule (35, 40 and 75 mg) and suspension formulations are now readily available. Oseltamivir is ingested in the form of an oral prodrug (oseltamivir phosphate, OP) that is rapidly metabolized to the active form, oseltamivir carboxylate (OC) (Figure 1). In infected patients, OC binds to and inhibits the active site of the neuraminidase enzymes that are present on all influenza viruses and are essential for the release of progeny virions from infected host cells (Figure 2). In this way, OC can reduce viral replication, which in turn can limit the viral load and course of infection in the host. When started within 48 h of the onset of illness, this action can limit the severity and duration of the symptoms of influenza and the risk of associated complications, such as bronchitis, pneumonia and otitis media. Symptomatic illness can also be prevented with prophylactic administrations.

Since the active site of the neuraminidase enzyme is highly conserved, oseltamivir has activity against all of the neuraminidase subtypes so far tested in vitro. These include the neuraminidases of human seasonal viruses, avian viruses and pandemic viruses, including the newly emergent pandemic (H1N1) 2009 virus. A variety of laboratory strains and clinical isolates have shown susceptibility to OC, with 50% inhibitory concentrations (IC50s) ranging from 0.01 to 69.2 nM, depending on the influenza strain (Table 1). To place this in context, the average minimum plasma concentration of OC achieved with the twice-daily treatment regimen at the standard 75 mg dose is ~330 nM. Importantly, OC is highly selective for influenza neuraminidase, and shows little or no activity against neuraminidases of other viruses, bacteria or human liver microsomes.

Pharmacokinetics of oseltamivir and OC

To effectively limit viral replication and the viral load, therapeutic concentrations of OC must be achieved at all sites of infection and maintained for the duration of the dosing interval. For this
reason, the pharmacokinetic profiles of oseltamivir and OC have been extensively studied in healthy volunteers and infected patients. Inter- and intra-subject variability across different demographic populations has also been widely investigated.

**Absorption, distribution, metabolism and elimination**

Following oral administration of OP, oseltamivir is rapidly absorbed from the gastrointestinal tract and converted by hepatic esterases into the active metabolite OC, giving an absolute bioavailability of ~80%. OC is detectable in plasma within 30 min of dosing, and concentrations reach near-maximal levels after 3–4 h, exceeding oseltamivir concentrations by >20-fold. OC plasma concentrations display minimal inter- and intra-subject variability, and concomitant food intake has little effect on bioavailability.

The absorption rate of oseltamivir is unaffected under conditions of altered gastric pH, such as that induced by cimetidine and antacids.

The volume of distribution of OC after intravenous administration in man is 23–26 L. This value is similar to the extracellular volume of body water in humans, suggesting that the metabolite may penetrate infection sites at concentrations similar to those in plasma. Indeed, oseltamivir and OC are systemically distributed, with therapeutic concentrations attained in the lung, trachea and nasal mucosa, as well as the sinuses.

![Diagram](https://example.com/diagram.png)
OP.4,11 Neither oseltamivir nor OC interacts with human cytochrome P450 mixed-function oxidases or glucuronyl transferases; however, they are also eliminated in faeces.4 Following oral dosing, plasma concentrations of oseltamivir decline rapidly (apparent elimination half-life of 1–3 h), while OC concentrations persist for longer (apparent elimination half-life of 6–10 h), permitting twice-daily administration. Renal clearance of both compounds exceeds the glomerular filtration rate, indicating that renal tubular secretion contributes to elimination; for OC, this has been shown to proceed via the anionic transport process.4,11

Table 1. Inhibitory concentrations (IC_{50}s) of oseltamivir carboxylate against different neuraminidase subtypes in vitro.5,7–9

| Virus subtype | IC_{50} (nM) |
|---------------|-------------|
| H1N1          | 0.78–2.2     |
| H1N9          | 0.35         |
| H2N2          | 0.35–9.0     |
| H2N3          | 0.01–3.3     |
| H3N2          | 0.28–0.6     |
| H3N8          | 0.85         |
| H4N6          | 0.45–3.2     |
| H4N8          | 69.2         |
| H5N1          | 7.0          |
| H5N3          | 2.9          |
| H6N1          | 36.1         |
| H6N2          | 0.84         |

and middle ear (Figure 3).12 Eisenberg et al.13 also confirmed that OC reached the lung following oral dosing in rats, and was detected in the bronchoalveolar lining fluid with equal or greater exposure to that in plasma and a slower clearance.

At least 75% of an oral dose of the prodrug is converted into OC by first-pass metabolism, and <5% is recovered in urine as OP.4,11 Neither oseltamivir nor OC interacts with human cytochrome P450 mixed-function oxidases or glucuronyl transferases in vitro. OP and OC are eliminated primarily by renal excretion, but small amounts (<20% of the oral dose) of both compounds are also eliminated in faeces.4 Following oral dosing, plasma concentrations of oseltamivir decline rapidly (apparent elimination half-life of 1–3 h), while OC concentrations persist for longer (apparent elimination half-life of 6–10 h), permitting twice-daily dosing. Renal clearance of both compounds exceeds the glomerular filtration rate, indicating that renal tubular secretion contributes to elimination; for OC, this has been shown to proceed via the anionic transport process.4,11

Oseltamivir has shown a high safety margin in acute, sub-acute and chronic toxicity studies.4 The pharmacokinetics of oseltamivir are linear and dose proportional at doses of up to 500 mg twice daily.6,11 Only modest accumulation (<2-fold) of OC is noted prior to attainment of steady state. The pharmacokinetics of multiple dose administration can be predicted from those of single dosing and provide no indication of a temporal change in the disposition of either oseltamivir or OC. Steady-state plasma concentrations of OC are achieved within 2–3 days of twice-daily administration.4,11 Recently, the pharmacokinetics of high doses of oseltamivir have been examined in healthy Thai volunteers.14 In a dose-escalation study, 21 individuals received single doses of oseltamivir at four increasing dose levels, giving a total of 125 individual series. Doses of up to 675 mg were well tolerated. Pharmacokinetics were dose-linear, with rapid absorption and conversion (median = 93%) into OC. Median [95% confidence interval (CI)] elimination half-lives were 1.0 (0.9–1.1) h for oseltamivir and 5.1 (4.7–5.7) h for OC. One subject repeatedly showed markedly reduced conversion of oseltamivir into OC due to constitutionally impaired carboxylesterase activity.14

### Influence of patient demographics and ethnicity

Overall, there are no clinically relevant differences in the pharmacokinetics of oseltamivir or OC between healthy volunteers and infected patients; this applies in adults of different sexes, ages and weights.11 Equally, ethnicity does not appear to affect the pharmacokinetics of the prodrug or active metabolite. In a study in which healthy Japanese and Caucasian subjects were randomized to 75 or 150 mg of oseltamivir or placebo twice daily for 6 days, with a single dose on day 7, individual and mean pharmacokinetics of oseltamivir and OC were similar between the two groups (Figure 4).15 Ethnic differences produced no observable effect on individual exposures at steady state. Although a prospective comparison has not been performed in children, data from four separate studies involving 141 Caucasian and 18 Japanese children have been pooled to compare plasma concentrations.16 After normalization to a 2 mg/kg dose, interquartile ranges for oseltamivir concentration were 3.63–26.75 ng/mL (Caucasian) and 3.95–22.05 ng/mL (Japanese). Results for OC were very similar.

### Influence of renal or hepatic impairment

Exposure to OC is increased as a result of decreased renal function, and severe renal insufficiency (creatinine clearance rates of <30 mL/min) is associated with a marked increase in exposure.4,17 In this patient group, a reduced treatment dose of 75 mg once daily is recommended.3 Oseltamivir is not recommended for patients with end-stage renal disease (creatinine clearance <10 mL/min). In vitro experiments indicate that the metabolic pathway of oseltamivir conversion into OC in the liver is unlikely to be appreciably altered in subjects with moderate hepatic impairment.18 This has been confirmed in a clinical study, and no dose adjustment is recommended for patients with mild to moderate hepatic impairment.11

### Influence of age

Exposure to oseltamivir in elderly patients increases in proportion to the usual age-related decline in renal function.4,11,19 However,
as this increase is small relative to the known safety margin, no
dose adjustment is necessary. There are no clinically relevant
differences in the pharmacokinetics of oseltamivir or OC
between healthy children and infected children. Clearance of
OC increases with increasing body weight, and hence age, and
this is particularly apparent when the OC clearance is expressed
per kg of body weight. The OC rate of clearance per kg of body
weight in children decreases with advancing age, such that
exposure in children aged 3–16 years is similar to that in adults.20

Although the range of exposures in children and adolescents
≤16 years following a 2 mg/kg oseltamivir dose was within the
range that was safe and effective in adults receiving 75 or
150 mg doses twice daily, there was a clear trend towards
higher systemic clearance per kg of body weight in younger chil-
dren. Administration of 2 mg/kg to children in the age range 3–
16 years demonstrated a significant downward trend with
decreasing age (Figure 5). Therefore, a simple age- and weight-
Based unit dosing algorithm was developed to ensure exposures
in children comparable to those in adults. The algorithm
is based on a target exposure window and a simple linear regression
analysis of pharmacokinetic data from children and adolescents
following a single 2 mg/kg dose of oseltamivir. The algorithm
was shown to maintain drug exposure within the target efficacy/
safety window, while also allowing for a convenient dose regimen.20

Drug interactions

Patients with influenza often take over-the-counter medications
to ease their symptoms. In addition, many patients with
comorbidities receive concomitant drugs. Drug interactions could
adversely affect the pharmacokinetics of the co-administered
medications, and thus their efficacy and safety. With this in mind,
the potential for clinically relevant interactions between oseltamivir
and OC and a variety of commonly used medications has been
widely studied.

Oseltamivir has limited potential for clinically relevant inter-
actions with commonly co-administered drugs. When oseltamivir
was taken with paracetamol (acetaminophen), plasma concen-
trations of OC and paracetamol remained unaffected. Equally,
co-administration of aspirin or antacids with oseltamivir had
no relevant effect on the pharmacokinetics of these compounds.
Further studies indicated that neither cimetidine nor amoxicillin
exhibited any interaction with oseltamivir. Furthermore, the
latter investigation confirmed that oseltamivir is a weak competi-
tor for the anionic renal tubular secretion processes and that its
potential to compete effectively with other organic acids that
undergo renal tubular secretion is minimal. Care should be
taken with medications with a narrow therapeutic margin that
are co-excreted, e.g. methotrexate. In renal transplant patients,
co-administration of oseltamivir was shown not to change the
pharmacokinetics of the immunosuppressive drugs cyclosporin,
mofetil and tacrolimus, and the

![Figure 4](https://academic.oup.com/jac/article-abstract/65/suppl_2/ii5/773394)
![Figure 5](https://academic.oup.com/jac/article-abstract/65/suppl_2/ii5/773394)
pharmacokinetics of oseltamivir itself in these patients were found to be similar to those in patients with native kidneys.\(^{26}\)

Several groups have studied the co-administration of oseltamivir and probenecid.\(^{14,25,26}\) The ability of probenecid to modify the renal secretion of other drugs has previously been exploited, and its use as a ‘sparking agent’ to extend oseltamivir supplies in the event of an influenza pandemic has been suggested.\(^{27,28}\) In one study, co-administration of oseltamivir and probenecid resulted in an increase of \(-2.5\)-fold in exposure to OC, indicating that tubular secretion of the latter proceeds via the anionic pathway.\(^{23}\) Although this pathway is shared by some other drugs, clinically relevant interactions are unlikely. A more recent investigation found a mean decrease in the apparent volume of OC distribution of 40% (95% CI, 37%–44%) and mean reduction in renal elimination of 61% (58%–62%), resulting in an increase in the median AUC for OC of 154% (range, 71%–278%).\(^{14}\)

Two groups have recently investigated the pharmacokinetics of oseltamivir/probenecid combinations in more detail.\(^{25,26}\) In the first of these, Holodniy et al.\(^{25}\) compared the pharmacokinetics of the combination (oseltamivir 75 mg once every 48 h plus probenecid 500 mg four times a day) with oseltamivir alone (75 mg once daily). Oral clearance of OC was found to be \(-25\)% lower with the combination, and 48 h plasma exposure results showed a lack of bioequivalence. However, the mean trough concentrations of OC at the end of a dosing interval in the two groups were not significantly different, suggesting that co-administration of probenecid might allow reduction of oseltamivir dose without compromising neuraminidase inhibition.\(^{25}\) In the second study, Rayner et al.\(^{26}\) used a population pharmacokinetic model to simulate combination regimens of oral oseltamivir (45 and 30 mg twice daily) and oral probenecid (500 mg/6 hourly). Probenecid plus 45 mg of oseltamivir achieved all the pharmacokinetic parameters expected of oseltamivir alone, but combination with 30 mg of oseltamivir and dose interval extension approaches did not.\(^{26}\) It is noteworthy, however, that unsuitable oseltamivir/probenecid regimens, or non-compliance with suitable regimens, could increase the risk of resistance in resistant virus via suboptimal dosing. Moreover, co-administration could compromise the systemic distribution of OC, which could be vital in cases of infection with highly pathogenic virus. Alongside the potential for multiple, clinically relevant drug interactions and adverse events with probenecid, the utility of the combination strategy appears to be limited.\(^{26}\)

Oseltamivir has not previously been associated with haematological adverse reactions or interference with the coagulation process. However, following sporadic post-marketing reports of bleeding in patients on anticoagulant therapy, the pharmacokinetic interaction between the agents was re-evaluated in 20 patients receiving daily warfarin and with international normalized ratio (INR) values of 2.0–3.5 during the previous 2 weeks.\(^{29}\) These volunteers were randomized to twice-daily 75 mg of oseltamivir for 4 days with a single 75 mg dose on day 5, or warfarin alone in a two-way crossover design separated by a wash-out of 4–8 days. Anticoagulant effects were assessed by calculating overall change (AUEC\(_{0–9}\)) and maximum absolute change from baseline (\(E_{\text{max}}\)) in INR and Factor VIIa, and change in vitamin K1 concentrations. For both treatments, changes from baseline in INR and Factor VIIa during treatment were small and there were also no statistically significant differences between treatments in mean \(E_{\text{max}}\) for INR and Factor VIIa, or in the change from baseline in vitamin K1 concentration. Oseltamivir did not alter warfarin pharmacokinetics. Oseltamivir was well tolerated in this population, with no adverse safety findings.\(^{29}\)

### Conclusions

Osalteamivir is an orally administered antiviral for the treatment and prophylaxis of influenza A and B infections in adults and children aged \(\geq 1\) year. After dosing, the prodrug (OP) is readily absorbed from the gastrointestinal tract and rapidly converted into the active metabolite, OC. In all patient groups, OC has high bioavailability and is systemically distributed to infection sites at concentrations sufficient to inhibit a range of influenza virus neuraminidases. Oseltamivir has a predictable linear pharmacokinetic profile and is suitable for a variety of patient populations and age groups. The potential for clinically relevant drug interactions is low. These characteristics underpin the use of oseltamivir in the diverse patient populations that are likely to be affected by seasonal and pandemic influenza viruses.

### Funding

Funding for this manuscript and the Supplement to which it belonged was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland, the manufacturer of oseltamivir.

Funding for the medical writing support was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

### Transparency declarations

This article is part of a Supplement sponsored by F. Hoffmann-La Roche Ltd.

The author is employed by F. Hoffmann-La Roche Ltd.

Medical writing support (drafting of text and editorial assistance) for this manuscript was provided by Scott Malkin and Stephen Purver of Gardiner-Caldwell Communications Ltd, Macclesfield, UK.

### References

1. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, eds. *Textbook of Influenza*. Oxford, UK: Blackwell Science, 1998; 219–64.

2. Moscona A. Neuraminidase inhibitors for influenza. *N Engl J Med* 2005; 353: 1363–73.

3. Tamiflu SmPC. *Tamiflu Summary of Product Characteristics*. http://emc.medicines.org.uk/ (22 October 2009, date last accessed).

4. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. *Clin Pharmacokin* 1999; 37: 471–84.

5. Roberts NA, Wiltshire HR, Mendel DB et al. Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase. In: *Abstracts of the ASM Biodefense Research Meeting*, Baltimore, 2003. Poster.

6. WHO. Pandemic (H1N1) 2009 - Update 65. http://www.who.int/csr/don/2009_09_11/en/index.html (23 October 2009, date last accessed).

7. Leneva IA, Roberts N, Govorkova EA et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. *Antiviral Res* 2000; 48: 101–15.

8. Bantio S, Parker CD, Ananth SL et al. Comparison of the anti-influenza virus activity of RWU-270201 with those of oseltamivir and zanamivir. *Antimicrob Agents Chemother* 2001; 45: 1162–7.
Abe M, Smith J, Urae A. Metabolite oseltamivir carboxylate. Impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol 2005; 59: 598–601.

19 Abe M, Smith J, Urae A et al. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann Pharmacother 2006; 40: 1724–30.

20 Oo C, Barrett J, Hill G et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs 2001; 3: 229–36.

21 Oo C, Barrett J, Dorr A et al. Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin. Antimicrob Agents Chemother 2002; 46: 1993–5.

22 Snell P, Oo C, Dorr A et al. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Br J Clin Pharmacol 2002; 54: 372–7.

23 Hill G, Cihlar T, Oo C et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion—correlation of in vivo and in vitro studies. Drug Metab Dispos 2002; 30: 13–9.

24 Aoki F, Lam H, Jeffrey JR et al. Oseltamivir does not interact pharmacokinetically with cyclosporine, mycophenolate or tacrolimus in renal transplant patients. In: Abstracts of the Annual Meeting of the Infectious Diseases Society of America, San Francisco, 2005. Abstract 522. Infectious Diseases Society of America, Arlington, VA, USA.

25 Holodniy M, Penzak SR, Straight TM et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008; 52: 3013–21.

26 Rayner CR, Chanu P, Gieschke R et al. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol 2008; 48: 935–47.

27 Butler D. Wartime tactic doubles power of scarce bird-flu drug. Nature 2005; 438: 6.

28 Howton JC. Probenecid with oseltamivir for human influenza A (H5N1) virus infection? N Engl J Med 2006; 354: 879–80.

29 Davies BE, Aceves Baldo P, Brewster M. Effect of oseltamivir on anticoagulation: a crossover study in patients stabilized on warfarin. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2009. Abstract A1-596.

American Society for Microbiology, Washington, DC, USA.